R. Bryan Rumble

Nov 6, 2023 | brnw.ch | R. Bryan Rumble |Rahul Parikh

In 2014, ASCO published a guideline on systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC),1 which was updated2 in 2022 to include guidance on the use of 177Lutetium-PSMA-617 (177Lu-PSMA-617), a radioligand therapy that delivers targeted beta-particle radiation to prostate-specific membrane antigen (PSMA)–expressing cancer cells.